🇺🇸 UTHR — United Therapeutics Corporation
Salud CompraPrecio actual
601,32 USD
Máx. histórico
601,32
0 días
Split 2:1 del 23/09/2009
Caída desde máximo
En máximo
Rango 52 semanas
430,02 – 609,99
Variación hoy
+0,87%
Cierre anterior
596,13
Rango de hoy
596,14 – 606,16
Volumen hoy
595.233
Peor caída histórica
-93,18%
12/07/2000 → 10/12/2001
Recuperado en 3311 días
Volatilidad anualizada ⓘ
46,95%
- Nombre completo
- United Therapeutics Corporation
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- Empleados
- 1.400
- PER ⓘ
- 21,54 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 670,93 USD (puede no estar actualizado)
- Primera cotización
- 17/06/1999
- Precio actualizado
- hace 20 horas
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Fecha | Ratio |
|---|---|
| 23/09/2009 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/03/2003 | 8,50 | 8,64 | 8,48 | 8,49 | -1,28% | 1,82% | 174.200 |
| 25/03/2003 | 8,47 | 8,68 | 8,47 | 8,60 | +1,42% | 2,42% | 215.000 |
| 24/03/2003 | 8,54 | 8,60 | 8,33 | 8,48 | -0,82% | 3,10% | 202.000 |
| 21/03/2003 | 8,44 | 8,66 | 8,41 | 8,55 | +1,24% | 2,96% | 625.400 |
| 20/03/2003 | 8,40 | 8,53 | 7,99 | 8,45 | -0,06% | 6,43% | 316.800 |
| 19/03/2003 | 8,43 | 8,53 | 8,30 | 8,45 | +0,24% | 2,67% | 366.000 |
| 18/03/2003 | 8,51 | 8,54 | 8,29 | 8,43 | -1,06% | 3,00% | 226.200 |
| 17/03/2003 | 8,05 | 8,52 | 8,05 | 8,52 | +5,38% | 5,84% | 520.600 |
| 14/03/2003 | 8,11 | 8,18 | 8,06 | 8,09 | -0,19% | 1,48% | 541.800 |
| 13/03/2003 | 7,90 | 8,18 | 7,90 | 8,10 | +2,21% | 3,48% | 618.400 |
| 12/03/2003 | 7,75 | 7,95 | 7,75 | 7,93 | +1,21% | 2,52% | 305.000 |
| 11/03/2003 | 7,82 | 7,86 | 7,73 | 7,83 | -0,19% | 1,66% | 218.200 |
| 10/03/2003 | 7,90 | 7,90 | 7,78 | 7,85 | -0,70% | 1,58% | 121.200 |
| 07/03/2003 | 7,90 | 7,95 | 7,86 | 7,90 | +0,00% | 1,20% | 297.000 |
| 06/03/2003 | 7,89 | 7,97 | 7,80 | 7,90 | +0,06% | 2,09% | 228.600 |
| 05/03/2003 | 7,98 | 7,98 | 7,88 | 7,90 | -1,25% | 1,25% | 249.400 |
| 04/03/2003 | 8,02 | 8,05 | 7,97 | 8,00 | -0,12% | 1,06% | 335.000 |
| 03/03/2003 | 7,95 | 8,01 | 7,90 | 8,01 | +1,33% | 1,32% | 543.200 |
| 28/02/2003 | 7,53 | 8,00 | 7,53 | 7,90 | +2,66% | 6,31% | 260.400 |
| 27/02/2003 | 7,60 | 7,75 | 7,59 | 7,70 | +0,65% | 2,11% | 202.400 |
| 26/02/2003 | 7,64 | 7,70 | 7,46 | 7,65 | -0,39% | 3,21% | 252.400 |
| 25/02/2003 | 7,83 | 7,91 | 7,45 | 7,68 | -0,26% | 5,81% | 616.600 |
| 24/02/2003 | 7,60 | 7,70 | 7,55 | 7,70 | -0,06% | 2,04% | 764.600 |
| 21/02/2003 | 7,61 | 7,75 | 7,59 | 7,70 | +1,52% | 2,17% | 292.400 |
| 20/02/2003 | 7,73 | 7,75 | 7,53 | 7,59 | -1,94% | 2,91% | 64.600 |
| 19/02/2003 | 7,75 | 7,75 | 7,68 | 7,74 | +0,13% | 0,97% | 106.200 |
| 18/02/2003 | 7,56 | 7,75 | 7,56 | 7,73 | +1,78% | 2,51% | 304.200 |
| 14/02/2003 | 7,52 | 7,65 | 7,51 | 7,59 | +1,07% | 1,93% | 213.800 |
| 13/02/2003 | 7,50 | 7,51 | 7,33 | 7,51 | +1,69% | 2,40% | 255.400 |
| 12/02/2003 | 7,46 | 7,50 | 7,36 | 7,39 | -1,86% | 1,88% | 114.000 |